Aligos Therapeutics, Inc. (NASDAQ:ALGS) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Aligos Therapeutics, Inc. (NASDAQ:ALGS) has been given a consensus recommendation of “Moderate Buy” by the seven research firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, five have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $38.50.

Several analysts have issued reports on the company. Weiss Ratings raised Aligos Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, July 10th. Wall Street Zen upgraded Aligos Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Sunday, May 17th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Aligos Therapeutics in a research report on Friday, May 29th. Finally, Lake Street Capital began coverage on Aligos Therapeutics in a research note on Thursday, May 28th. They issued a “buy” rating and a $45.00 target price on the stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. Geode Capital Management LLC boosted its position in shares of Aligos Therapeutics by 21.3% in the 2nd quarter. Geode Capital Management LLC now owns 34,048 shares of the company’s stock worth $246,000 after purchasing an additional 5,978 shares in the last quarter. Rockefeller Capital Management L.P. raised its stake in Aligos Therapeutics by 900.0% in the fourth quarter. Rockefeller Capital Management L.P. now owns 10,000 shares of the company’s stock valued at $93,000 after buying an additional 9,000 shares during the last quarter. SummitTX Capital L.P. raised its stake in Aligos Therapeutics by 6.7% in the first quarter. SummitTX Capital L.P. now owns 148,799 shares of the company’s stock valued at $1,106,000 after buying an additional 9,375 shares during the last quarter. Susquehanna International Group LLP acquired a new stake in Aligos Therapeutics in the third quarter worth about $99,000. Finally, LPL Financial LLC boosted its holdings in Aligos Therapeutics by 19.7% in the fourth quarter. LPL Financial LLC now owns 66,000 shares of the company’s stock worth $615,000 after acquiring an additional 10,880 shares in the last quarter. Hedge funds and other institutional investors own 60.43% of the company’s stock.

Aligos Therapeutics Stock Performance

NASDAQ ALGS opened at $4.25 on Wednesday. The firm’s 50 day moving average price is $5.48 and its 200-day moving average price is $6.64. Aligos Therapeutics has a 52-week low of $3.98 and a 52-week high of $13.69. The company has a market cap of $26.31 million, a PE ratio of -0.49 and a beta of 2.26.

Aligos Therapeutics (NASDAQ:ALGS) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($2.21) EPS for the quarter, topping analysts’ consensus estimates of ($2.29) by $0.08. The company had revenue of $2.83 million during the quarter, compared to the consensus estimate of $0.25 million. Aligos Therapeutics had a negative net margin of 1,919.68% and a negative return on equity of 139.47%. On average, analysts forecast that Aligos Therapeutics will post -7.47 earnings per share for the current fiscal year.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.